A detailed history of Byrne Asset Management LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Byrne Asset Management LLC holds 3,633 shares of GILD stock, worth $319,994. This represents 0.21% of its overall portfolio holdings.

Number of Shares
3,633
Previous 12,205 70.23%
Holding current value
$319,994
Previous $894,000 72.15%
% of portfolio
0.21%
Previous 0.74%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 23, 2024

SELL
$63.15 - $72.88 $541,321 - $624,727
-8,572 Reduced 70.23%
3,633 $249,000
Q1 2024

Apr 22, 2024

SELL
$71.58 - $87.29 $27,701 - $33,781
-387 Reduced 3.07%
12,205 $894,000
Q4 2023

Jan 29, 2024

SELL
$73.27 - $83.09 $6,594 - $7,478
-90 Reduced 0.71%
12,592 $1.02 Million
Q3 2023

Oct 31, 2023

SELL
$73.94 - $80.67 $51,018 - $55,662
-690 Reduced 5.16%
12,682 $950,000
Q2 2023

Jul 21, 2023

BUY
$76.01 - $86.7 $26,223 - $29,911
345 Added 2.65%
13,372 $1.03 Million
Q1 2023

Apr 17, 2023

SELL
$77.31 - $88.08 $46,772 - $53,288
-605 Reduced 4.44%
13,027 $1.08 Million
Q4 2022

Jan 30, 2023

SELL
$62.32 - $89.47 $95,972 - $137,783
-1,540 Reduced 10.15%
13,632 $1.17 Million
Q3 2022

Oct 19, 2022

SELL
$59.54 - $68.01 $12,205 - $13,942
-205 Reduced 1.33%
15,172 $936,000
Q2 2022

Jul 20, 2022

BUY
$57.72 - $65.01 $14,430 - $16,252
250 Added 1.65%
15,377 $950,000
Q1 2022

Apr 05, 2022

BUY
$57.92 - $72.58 $160,728 - $201,409
2,775 Added 22.47%
15,127 $899,000
Q4 2021

Feb 22, 2022

BUY
$64.88 - $73.64 $801,397 - $909,601
12,352 New
12,352 $897,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Byrne Asset Management LLC Portfolio

Follow Byrne Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Byrne Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Byrne Asset Management LLC with notifications on news.